Accordingly, using both in vitro and in vivo NB model, we investigated whether EF24 could selectively target and inhibit RT-induced NFκB-TNFα-NFκB cross signaling-dependent persistent activation of NFκB and thereby offer a comprehensive and complete prevention of NFκB-mediated survival advantage, clonal expansion and tumor relapse. This evidence concerns the gene NFKB1 and neuroblastoma.